What are the contraindications and precautions for Pitobrutinib?

Pirtobrutinib, also known as Jaypirca or LOXO-305, is a kinase inhibitor produced by Lilly USA, LLC. It is primarily indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two systemic therapies, including BTK inhibitors. Pitobrutinib, as a third-generation BTK inhibitor, provides a new treatment option for patients with drug resistance, disease progression, or intolerance with its unique non-covalent (reversible) binding mechanism.

However, patients and physicians need to pay special attention to the following contraindications and precautions when using pitobrutinib:

Infection or weak immune system: Pitobrutinib may increase your risk of infection. Patients with weakened immune systems or who are at higher risk for infection should be closely monitored for signs and symptoms of infection and treated promptly.

Bleeding problems: Pitobrutinib may cause bleeding events. Patients at risk for serious bleeding should use this drug with caution and monitor for bleeding.

Heart problems: Pitobrutinib may cause heart problems, such as arrhythmias. Patients with cardiovascular disease such as arrhythmia, heart disease, or hypertension should use with caution and have their heart monitored regularly.

Have had any other cancer before: Pitobrutinib may have a promoting effect on certain types of tumors. Therefore, patients who have previously suffered from any other cancer should consult their doctor before use.

Hypertension: Patients with hypertension should use special caution when using pitobrutinib because the drug may cause heart-related adverse effects.

Liver Problems: Pitobrutinib is metabolized and excreted primarily by the liver. Therefore, it should be used with caution in patients with severe hepatic impairment and may require dose adjustment or avoidance.

Kidney problems: Renal impairment may affect the metabolism and elimination of pitobrutinib. Dosage adjustments may be required in patients with severe renal impairment.

In addition, when using pitobrutinib, attention should be paid to interactions with other drugs, such as avoiding simultaneous use with strongCYP3A inhibitors or inducers, so as not to affect the efficacy or increase the risk of adverse reactions. Patients should strictly follow their doctor's recommendations and instructions while using Pitobrutinib, and regularly report any discomfort or adverse reactions to their doctor.

xa0

Reference: https://www.webmd.com/drugs/2/drug-185890/jaypirca-oral/details